INDV Stock Forecast & Price Target

Indivior Pharmaceuticals demonstrated a solid growth trajectory with approximately 171,500 patients on Sublocade treatment in Q3 2025, marking an 8% increase compared to the previous year, alongside an 11% rise in the number of prescribers. The company has adjusted its guidance for worldwide Sublocade sales to a range of $825 million to $845 million, signaling a robust annual growth potential of approximately 10% at the midpoint. Furthermore, the sustained demand for its products, combined with effective cost management, is expected to support a healthy long-term EBITDA compound annual growth rate, reinforcing a positive outlook for the stock.

Indivior Pharmaceuticals is facing significant challenges, evidenced by a drastic reduction in the commercial support for its primary product, Sublocade, which has seen its footprint shrink from approximately 40 countries to just four. Furthermore, the company has ceased commercial support for Opvee, indicating a strategic shift that has not generated positive synergies with its existing product line. Consensus projections suggest a decline in revenues of about 6.5% by 2026, primarily due to portfolio simplification actions in 2025, raising concerns about the company’s long-term growth prospects.